Dr. Michael H. Annabi, MD

Dr. Annabi practices at Michael H Annabi Mdpa in El Paso, Texas.

Dr. Annabi's NPI, 1962484378, was assigned on November 19, 2005. Dr. Annabi graduated from American University of the Caribbean School of Medicine in 1987. Dr. Annabi holds Texas license K6800.

Dr. Annabi's primary practice is Michael H Annabi Mdpa, at 4930 Osborne Dr Suite A Suite A, El Paso, TX 79922-1043. The practice phone is (915) 587-9455.

Dr. Annabi's primary practice is Michael H Annabi Mdpa in El Paso, Texas. Dr. Annabi is also affiliated with University Medical Center of El Paso. The medical group on file is El Paso Physical Therapy Services. Dmand AI also links Dr. Annabi to 4 more hospitals, 3 home health agencies and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Annabi practices, 9 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Annabi's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Annabi is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Annabi's licenses on file in 4 states: Texas, Florida, Pennsylvania and New Jersey.

Dmand AI lists acid reflux, acute diabetes, acute gastroduodenitis, acute respiratory failure, acute sinusitis, acute skin infection, anemia and aortic atherosclerois among the conditions Dr. Annabi treats.

CMS data shows 5,170 Medicare services from Dr. Annabi across 18 procedure codes in 2024, for 851 Medicare patients. Medicare paid $342,497 for them.

CMS counts 851 Medicare patients who saw Dr. Annabi in 2024. The largest group is 65 to 74, with 325 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Annabi's median patient age at 68, with 54% women.

In 2024, Dr. Annabi wrote 10,718 Medicare Part D claims for 1,181 patients. 75% of them were for generic drugs. CMS names the drug for 9,799 of them, across 168 drugs with 11 or more claims each, at $2,217,787 in total drug cost. In 2023, CMS named 8,650 claims across 144 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Annabi for performance year 2024, reported individually. Dr. Annabi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Annabi as offering telehealth.

Dmand AI links 3 papers to Dr. Annabi, published from 2017 to 2024. The most frequent topics are Biomarkers, Tumor and Prostatic Neoplasms. Dr. Annabi's most frequent co-authors are Thomas James Polascik, MD and Heinric Williams, MD.

CMS Open Payments shows 1,716 general payments to Dr. Annabi from 71 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 81% of the total. Novo Nordisk Inc paid the most, $107,570.

Dr. Annabi graduated from American University of the Caribbean School of Medicine in 1987.

Dr. Annabi is in network with 24 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.